Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV (MASH1)

NEAT ID Foundation

Status: Completed

Conditions: HIV Coinfection; Monkeypox

Treatments: Other: No intervention

Study type: Observational

Funder types: Other; NETWORK

Identifiers

NCT05965427

606

Details and patient eligibility

About

This data collection study aims to describe and compare the outcomes of Mpox on people living with HIV (PLHIV) and HIV-negative individuals who are on pre-exposure prophylaxis (PrEP). The study also aims to identify risk factors for specific Mpox outcomes.

Enrollment: 2,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of MPX was more than 90 days prior to data collection
• Confirmed MPX infection by documented PCR testing of lesions between 1st May 2022 to 1st December 2023
• At least 18 years of age
• Cases (PLWHIV + MPX) i) Documented HIV-1 infection
• Cases (PrEP users + MPX) i) Attended a clinic to receive PrEP

Exclusion criteria

• MPX diagnosed based on clinical criteria only
• MPX diagnosis was within the last 90 days

Trial design

2,000 participants in 2 patient groups

PLWHIV and Mpox coinfection

Description:

People living with HIV(PLWHIV) who are at least 18 years of age, with confirmed Mpox infection by documented, positive result on PCR testing of lesions from 1st May 2022 to 1st December 2023.

Treatment:

Other: No intervention

HIV negative PrEP users with Mpox infection

Description:

HIV negative PrEP (Pre-exposure prophylaxis) users who are at least 18 years of age, with confirmed Mpox infection by documented, positive result on PCR testing of lesions from 1st May 2022 to 1st December 2023.

Treatment:

Other: No intervention